Medtronic ((MDT)) announced an update on their ongoing clinical study.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Medtronic’s Mid-Q Response Study, officially titled the same, aimed to evaluate the effectiveness of the AdaptivCRT (aCRT) algorithm compared to standard CRT therapy in patients with specific heart conditions. The study’s primary objective was to determine if aCRT ON improves patient outcomes on the Clinical Composite Score (CCS) after six months.
The interventions tested were the aCRT ON, a CRT device with the AdaptivCRT algorithm enabled, and the aCRT OFF, where the algorithm was disabled. The purpose was to enhance patient outcomes by optimizing heart rhythm management.
The study was a prospective, multi-center, randomized controlled trial conducted in a parallel intervention model. Participants were randomly assigned to either the treatment group (aCRT ON) or the control group (aCRT OFF), with single masking applied to participants.
The study commenced on January 23, 2020, with primary completion in April 2025 and the last update in July 2025. These dates are crucial for tracking the study’s progress and data availability.
The study’s findings could influence Medtronic’s stock performance and investor sentiment, as positive outcomes might enhance the company’s competitive position in the cardiac device market. However, the results showed no significant differences between the groups, which might temper market enthusiasm.
The Mid-Q Response Study is completed, with further details accessible on the ClinicalTrials portal.